Abstract
Background: ST-Segment Elevation Myocardial Infarction (STEMI) is among the most prevalent heart diseases worldwide and a leading cause of death. Delayed thrombolytic treatment significantly increases mortality risk in affected patients. This study aimed to identify factors associated with delayed administration of thrombolytic medication in STEMI patients.
Methods: A cross-sectional analytical study was conducted in Narathiwat Province, involving 1,074 STEMI patients documented in the Acute Coronary Syndrome Registry between January 1, 2016, and December 31, 2021. Of these, 781 eligible patients were categorized into two groups: 464 with delayed thrombolytic medication and 317 without. Descriptive statistics and multiple logistic regression used for data analysis.
Results: The proportion of patients experiencing delayed thrombolytic medication was 59.4% (95% CI: 55.8-62.9). Factors such as the total number of underlying diseases, Killip classification, and timing of accessing health services were associated with delayed thrombolytic medication. Patients with four underlying diseases had a reduced risk of delayed thrombolytic medication (AOR = 0.40, 95% CI: 0.24-0.63). Conversely, those diagnosed with cardiogenic shock (Class IV) (AOR = 3.74, 95% CI: 1.94-7.20) and those accessing services at night increased risk of delayed thrombolytic mediation (AOR = 2.16, 95% CI: 1.37-3.40).
Conclusion: The number of underlying diseases, Killip classification, and timing of health service access were linked to delayed thrombolytic medication. STEMI patients with advanced Killip classification, particularly those seeking care at night, should receive intensified attention to ensure timely administration of thrombolytic, thereby mitigating disease progression and reducing mortality.
Keywords: Delayed Thrombolytic Medication, ST-elevation myocardial infarction, Thrombolytic therapy, Thailand
Recommended Citation
Suemae M, Chaimay B, Woradet S.
Factors Associated with Delayed Thrombolytic Medication among Patients with ST-Segment Elevation Myocardial Infarction in Southern Thailand.
J Health Res.
2025;
39(1):-.
DOI: https://doi.org/10.56808/2586-940X.1121
References
[1] Nabel EG. Cardiovascular disease. N Engl J Med. 2003; 349: 60-72. doi: 10.1056/NEJMra035098
[2] Moleerergpoom W, Kanjanavanit R, Jintapakorn W, Sritara P. Costs of payment in Thai acute coronary syndrome patients. J Med Assoc Thai 2007; 90: 21-31. PMID: 18431883.
[3] Akbar H, Foth C, Kahloon RA, Mountfort S. Acute ST Elevation Myocardial Infarction. 2021 Aug 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
[4] Bergheanu SC, Bodde MC, Jukema JW, Pathophysiology and treatment of atherosclerosis. Neth Heart J 2017; 25: 231-42. doi: 10.1007/s12471-017-0959-2
[5] Kulek AR, Anzell A, Wider JM, Sanderson TH, Przyklenk K. Mitochondrial quality control: role in cardiac models of lethal ischemia-reperfusion injury. Cells 2020; 9: 214. doi: 10.3390/cells9010214
[6] Kim C, Chang HJ, Cho I, Sung JM, Choi D, Jeong MH, et al. Impact of family history on the presentation and clinical outcomes of coronary heart disease: data from the Korea Acute Myocardial Infarction Registry. Korean J Intern Med 2013; 28: 547-56. doi: 10.3904/kjim.2013.28.5.547
[7] World Health Organization. Cardiovascular diseases (CVDs). [internet]. Geneva: WHO; 2022 [cited 2022 Jul 16]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
[8] Reddy KS. Cardiovascular disease in non-western countries. N Engl J Med 2004; 350: 2438-40. doi: 10.1056/NEJMp048024
[9] Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation 2008; 118: 2702-9. doi: 10.1161/CIRCULATIONAHA.108.790048
[10] Tungsubutra W, Tresukosol D, Buddhari W, Boonsom W, Sanguanwang S, Srichaiveth B. Acute coronary syndrome in young adults: the Thai ACS Registry. J Med Assoc Thai 2007; 90: 81-90. PMID: 18431890
[11] Tangcharoensathien V, Faramnuayphol P, Teokul W, Bundhamcharoen K, Wibulpholprasert S. A critical assessment of mortality statistics in Thailand: potential for improvements. Bull of the World Health Organ 2006; 84: 233-8. doi: 10.2471/blt.05.026310
[12] Sanguanwong S, Srimahachota S, Tungsubutra W, Srichaiveth B, Kiatchoosakun S. Predictors of in-hospital mortality in Thai STEMI patients: results from TACSR. J Med Assoc Thai 2007; 90: 91-7. PMID: 18431891
[13] Lassen JF, Bøtker HE, Terkelsen CJ. Timely and optimal treatment of patients with STEMI. Nat Rev Cardiol 2013; 10: 41-8. doi: 10.1038/nrcardio.2012.156
[14] Limwattananon C, Jaratpatthararoj J, Thungthong J, Limwattananon P, Kitkhuandee A. Access to reperfusion therapy and mortality outcomes in patients with ST-segment elevation myocardial infarction under universal health coverage in Thailand. BMC Cardiovasc Disord 2020; 20(1): 1-10. doi: 10.1186/s12872-020-01379-3
[15] Trerayapiwat K, Jinatongthai P, Vathesatogkit P, Sritara P, Paengsai N, Dilokthornsakul P, et al. Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand. Lancet Reg Health West Pac 2022; 26: 100503. doi: 10.1016/j.lanwpc.2022.100503
[16] Alishahi Tabriz A, Sohrabi MR, Kiapour N, Yazdani S. Factors Associated with Delay in Thrombolytic Therapy in Patients with ST-Elevation Myocardial Infarction. J Tehran Heart Cent. 2012; 7(2): 65-71. PMID: 23074640.
[17] Tickley I, Van Blydenstein SA, Meel R. Time to thrombolysis and factors contributing to delays in patients presenting with ST-elevation myocardial infarction at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa. S Afr Med J. 2023; 113(9): 53-8. doi: 10.7196/SAMJ.2023.v113i9.500
[18] Koh HP, Md Redzuan A, Mohd Saffian S, Hassan H, R Nagarajah J, Ross NT. Mortality outcomes and predictors of failed thrombolysis following STEMI thrombolysis in a non-PCI capable tertiary hospital: a 5-year analysis. Intern Emerg Med. 2023; 18(4): 1169-80. doi: 10.1007/s11739-023-03202-1.
[19] De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004; 109(10): 1223-5. doi: 10.1161/01.CIR.0000121424.76486.20
[20] Ball D, Farrelly N. Interpreting 10 years of violence in Thailand’s deep south. Security Challenges 2012; 8(2): 1-18.
[21] Chirtkiatsakul B, Kuning M, McNeil N, Eso M. Risk factors for mortality among victims of provincial unrest in southern Thailand. Kasetsart J (Soc. Sci) 2014; 35: 84-91.
[22] Sukchan P, Chemoh W, Payanglee K. Morbidity and multi-morbidity among the elderly population in Southernmost Thailand: Cox Proportional Hazards Regression Model of Survival Approach. Princess of Naradhiwas University Journal 2020; 12: 89-105. [Thai].
[23] Bernard R. Fundamentals of biostatistics (5th Edition). Duxbury, Michigan; 2000.
[24] Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions (3rd Edition). John Wiley & Sons, Hoboken, New Jersey; 2003. doi: 10.1002/0471445428
[25] Ngamjarus C, Chongsuvivatwong V. n4Studies: Sample size and power calculations for iOS. The Royal Golden Jubilee Ph.D. Program - The Thailand Research Fund Prince of Songkla University. 2014.
[26] Mosleh W, Elango K, Shah T, Chaudhari M, Gandhi S, Kattel S, et al. Elevated end-diastolic wall stress after acute myocardial infarction predicts adverse cardiovascular outcomes and longer hospital length of stay. Echocardiography 2018; 35: 1721-8. doi: 10.1111/echo.14136
[27] Allahwala UK, Weaver JC, Bhindi R. Spontaneous coronary collateral recruitment in patients with recurrent ST elevation myocardial infarction (STEMI). Heart Vessels 2020; 35: 291-6. doi: 10.1007/s00380-019-01493-z
[28] Khot UN, Jia G, Moliterno DJ, Lincoff AM, Khot MB, Harrington RA, et al. Prognostic importance of physical examination for heart failure in Non-ST-Elevation Acute Coronary Syndromes: the enduring value of Killip Classification. JAMA 2003; 290: 2174–81. doi: 10.1001/jama.290.16.2174
[29] Hashmi KA, Adnan F, Ahmed O, Yaqeen SR, Ali J, Irfan M, et al. Risk assessment of patients after ST-Segment Elevation Myocardial Infarction by Killip Classification: an institutional experience. Cureus. 2020; 12: e12209. doi: 10.7759/cureus.12209
[30] Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-64. doi: 10.1016/0002-9149(67)90023-9
[31] Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N England J Med 2001; 345:574-81. doi: 10.1056/NEJMoa010641
[32] Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother 1996; 30: 55-61. doi: 10.1177/106002809603000110
[33] Heintzen MP, Strauer BE. Peripheral vascular effects of beta-blockers. Eur Heart J 1994; 15: 2-7. doi: 10.1093/eurheartj/15.suppl_c.2
[34] Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 2008; CD003823. doi: 10.1002/14651858.CD003823.pub2
[35] Lagerqvist B, Fröbert O, Olivecrona GK, Gudnason T, Maeng M, Alström P, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med 2014; 371: 1111-20. doi: 10.1056/NEJMoa1405707
[36] Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis. JACC Heart Fail 2015; 3: 647-53. doi: 10.1016/j.jchf.2015.03.008
